A randomized controlled trial of training of affect recognition (TAR) in schizophrenia shows lasting effects for theory of mind.


Journal

European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 30 11 2018
accepted: 22 02 2019
pubmed: 4 3 2019
medline: 10 1 2020
entrez: 4 3 2019
Statut: ppublish

Résumé

Schizophrenia is characterized by social cognitive impairments that predict functioning. Social cognitive training aims to target these impairments. Although it can improve the targeted social cognitive domain, it is unclear if the training generalizes to non-targeted domains and to functioning, with lasting effects. This randomized controlled trial examined the effect of a targeted facial affect recognition training program, Training of Affect Recognition (TAR), in persons with schizophrenia. Individuals with schizophrenia were randomized to receive treatment as usual and TAR (n = 24) or treatment as usual (n = 24) after assessments with a comprehensive protocol at baseline (T1). Participants were reassessed immediately after the intervention period (T2: after 8 weeks) and at 3-month follow-up (T3). The protocol included tests of social cognition (facial or body affect recognition, theory of mind), nonsocial cognition (Matrics Consensus Cognitive Battery), clinical symptoms (Positive and Negative Syndrome Scale, Calgary Depression Scale for Schizophrenia), functioning (self-reported, social or nonsocial functional capacity), self-esteem, self-efficacy and insight. Linear mixed models yielded a significant group × time interaction effect for a non-targeted social cognitive domain (theory of mind) and a trend-level effect for social functional capacity with the intervention group performing better over time. No beneficial effects on nonsocial cognition, other measures of functioning, clinical symptoms, or self-esteem/self-efficacy appeared for the TAR program. This study provides evidence for transfer and durability effects of facial affect recognition training to theory of mind, but also highlights the need for additional treatments to achieve functional benefits.

Identifiants

pubmed: 30826974
doi: 10.1007/s00406-019-00997-z
pii: 10.1007/s00406-019-00997-z
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

611-620

Subventions

Organisme : EkstraStiftelsen Helse og Rehabilitering
ID : 2011/3/0025
Organisme : Norwegian Council for Mental Health
ID : 2011/3/0025
Organisme : Helse Sør-Øst RHF
ID : 2010007
Organisme : Helse Sør-Øst RHF
ID : 2017069
Organisme : Helse Sør-Øst RHF
ID : 2014102

Références

Psychiatry Res. 2003 Mar 25;117(3):281-4
pubmed: 12686371
J Cogn Neurosci. 2004 Sep;16(7):1143-58
pubmed: 15453970
Schizophr Res. 2005 Dec 15;80(2-3):295-303
pubmed: 16125367
J Autism Dev Disord. 2006 Jul;36(5):623-36
pubmed: 16755332
Compr Psychiatry. 2007 Jan-Feb;48(1):88-94
pubmed: 17145287
Schizophr Bull. 2007 Nov;33(6):1364-72
pubmed: 17341468
Psychiatry Res. 2009 Mar 31;166(1):54-62
pubmed: 19193447
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88
pubmed: 20620163
Scand J Psychol. 2010 Dec;51(6):525-33
pubmed: 20642739
Schizophr Bull. 2012 Sep;38(5):1092-104
pubmed: 21525166
Schizophr Bull. 2011 Sep;37 Suppl 2:S41-54
pubmed: 21860046
Schizophr Bull. 2011 Sep;37 Suppl 2:S63-70
pubmed: 21860049
Schizophr Res. 2012 May;137(1-3):246-50
pubmed: 22356801
Schizophr Res. 2012 Jul;138(2-3):262-7
pubmed: 22464728
Psychiatry. 1990 Nov;53(4):329-39
pubmed: 2263676
Br J Psychiatry. 1990 Dec;157:853-9
pubmed: 2289094
Schizophr Bull. 2013 Sep;39(5):979-92
pubmed: 22949733
Clin Psychol Rev. 2012 Dec;32(8):724-40
pubmed: 23059624
J Clin Psychiatry. 2014;75 Suppl 2:14-9
pubmed: 24919166
Schizophr Res. 2015 Mar;162(1-3):42-6
pubmed: 25623602
Schizophr Bull. 2015 Jul;41(4):781-5
pubmed: 25750248
Psychiatry Res. 2015 Aug 30;228(3):803-7
pubmed: 26089018
Clin Psychol Rev. 2016 Feb;43:80-9
pubmed: 26437567
Front Psychol. 2016 Jan 14;6:2058
pubmed: 26834672
Psychol Med. 2016 Oct;46(13):2717-29
pubmed: 27649341
Schizophr Res. 2017 Oct;188:3-12
pubmed: 28095998
Cogn Neuropsychiatry. 2017 May;22(3):254-262
pubmed: 28346041
Schizophr Res. 2019 Jan;203:3-11
pubmed: 28712968
Psychiatry Res. 2018 Sep;267:37-47
pubmed: 29883859
J Psychiatr Res. 2018 Sep;104:65-71
pubmed: 29982084
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
J Clin Psychol. 1995 May;51(3):320-31
pubmed: 7560131
Acta Psychiatr Scand. 1994 Jan;89(1):62-7
pubmed: 7908156
Br J Psychiatry Suppl. 1993 Dec;(22):39-44
pubmed: 8110442

Auteurs

Anja Vaskinn (A)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway. anja.vaskinn@medisin.uio.no.
Department of Psychology, University of Oslo, Oslo, Norway. anja.vaskinn@medisin.uio.no.

André Løvgren (A)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway.

Maj K Egeland (MK)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway.
Department of Psychology, University of Oslo, Oslo, Norway.

Frida K Feyer (FK)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway.

Tiril Østefjells (T)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway.
Department for Specialized Inpatient Treatment, Division of Mental Health and Addiction, Akershus University Hospital, Lørenskog, Norway.

Ole A Andreassen (OA)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Ingrid Melle (I)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Kjetil Sundet (K)

Norwegian Centre for Mental Disorders Research, Oslo University Hospital, Oslo, Norway.
Department of Psychology, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH